Carvolix Appoints New Chair and Reports H1 2026 Results

Carvolix has appointed Anne Lange as Chair of its Board of Directors as it accelerates its strategic goals and announces its 2026 half-year results. Lange, with a background in senior management and board roles, brings extensive experience to her new position. She succeeds Liane Teplitsky, who remains a director.

The TAVIPILOT® platform has achieved key milestones, including positive clinical results and ongoing regulatory progress in Europe and the US, aiming for a commercial rollout early in 2027. The company also reported positive three-year clinical outcomes for the Kalios® mitral ring.

Financially, Carvolix secured €10 million in equity financing and €30 million in structured bond financing, ensuring resources through October 2027. Despite an increased operating loss of €14.4 million, the company focuses on expanding its commercial and clinical programs.